^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TNFRSF17 positive

    i
    Other names: TNFRSF17, TNF Receptor Superfamily Member 17, Tumor Necrosis Factor Receptor Superfamily Member 17, B-Cell Maturation Protein, BCMA, Tumor Necrosis Factor Receptor Superfamily, Member 17, B Cell Maturation Antigen, B-Cell Maturation Factor, CD269 Antigen, TNFRSF13A, CD269
    Entrez ID:
    608
    Related biomarkers:
    Expression
    CNA
    Others
    over1year
    Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. (PubMed, Cytometry B Clin Cytom)
    We demonstrated that BCMA/CD269 is highly expressed in aPCs from a majority of MM patients, both at diagnosis and relapse. Thus, BCMA is a valuable target for therapy for Indian MM patients.
    Journal • IO biomarker
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17)
    |
    TNFRSF17 positive
    2years
    CD269, CD319 EXPRESSION ON MALIGNANT PLASMA CELLS AND SOLUBLE BCMA, SLAMF7 PROTEINS COMPARATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (EHA 2022)
    Whereas, 100% sBCMA detection in NDMM patients was not followed by CD269 detection on malignant PC in half of the patients. These findings may indicate both the heterogeneity of MM and the necessity for further studies of sBCMA and sSLAMF7 to determine their prognostic significance.
    Clinical • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • TNFRSF17 (TNF Receptor Superfamily Member 17) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • CD27 (CD27 Molecule) • SLAMF7 (SLAM Family Member 7)
    |
    TNFRSF17 positive
    almost3years
    The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    CD319 and CD269 express stably and continuously in plasma cells of MM patients at different disease stages. CD319 can be used as an alternative of CD38 for immunophenotyping and MRD detection, especially for MRD detection after DARA treatment, while CD269 is suitable for detection before BCMA-CAR-T treatment.
    Clinical • Journal • IO biomarker • Minimal residual disease
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17) • SDC1 (Syndecan 1)
    |
    CD38 expression • TNFRSF17 expression • CD19 expression • TNFRSF17 positive